Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases

Renal squamous cell carcinoma (RSCC) is an uncommon malignancy, representing less than 1% of all renal cancers, and is associated with a notably poor prognosis. Surgical intervention is the primary treatment modality for early and intermediate-stage cases; however, the efficacy of combined chemoradiotherapy and immunotherapy in advanced-stage patients remains unclear. In this report, we present a case of RSCC with pulmonary metastases, wherein the patient attained disease remission following a treatment regimen comprising combined chemo-radiotherapy and immunotherapy. The patient demonstrated a progression-free survival (PFS) of 12 months and an overall survival (OS) of 14 months. This case study aims to provide a comprehensive analysis of the treatment approach, potentially serving as a reference for therapeutic strategies in patients with inoperable RSCC.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-08-08
DOI
https://doi.org/10.3389/fimmu.2025.1645909
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases

Zhiguo Luo, Xinzhou Deng, Yanlin Niu, Min Luo et al.
Frontiers in Immunology
Renal cell carcinoma treatment
article

Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases

Zhiguo Luo, Xinzhou Deng, Yanlin Niu, Min Luo, Shengchao Wang, Jiamin Chai
article en

Abstract

Renal squamous cell carcinoma (RSCC) is an uncommon malignancy, representing less than 1% of all renal cancers, and is associated with a notably poor prognosis. Surgical intervention is the primary treatment modality for early and intermediate-stage cases; however, the efficacy of combined chemoradiotherapy and immunotherapy in advanced-stage patients remains unclear. In this report, we present a case of RSCC with pulmonary metastases, wherein the patient attained disease remission following a treatment regimen comprising combined chemo-radiotherapy and immunotherapy. The patient demonstrated a progression-free survival (PFS) of 12 months and an overall survival (OS) of 14 months. This case study aims to provide a comprehensive analysis of the treatment approach, potentially serving as a reference for therapeutic strategies in patients with inoperable RSCC.

Frontiers in ImmunologyVol. 16
Hubei University of Medicine (CN)
Natural Science Foundation of Hubei Province, Special Project of Central Government for Local Science and Technology Development of Hubei Province
Good health and well-being
Openalex Percentile: Top 69%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Case Report: The integration of chemoradiotherapy and immunotherapy in a patient with advanced-stage renal squamous cell carcinoma and pulmonary metastases — Zhiguo Luo, Xinzhou Deng, et al. · Frontiers in Immunology (2025) | TGRS Research Map | TGRS